Abstract: A bone grafting material composite is provided. The bone grafting material composite includes a demineralized bone matrix (DBM) and a carboxymethyl cellulose (CMC)/glycerol gel carrier. Due to the CMC/glycerol gel carrier, the implantation ability thereof is better than that of the DBM. Therefore, the bone grafting material composite can be easily used, so that a curative effect can be greatly improved. In addition, since the CMC/glycerol gel is used as a carrier, the composite with a mobility maintained is washed out by water after surgery, so that the composite can be fixed on a damaged portion of a bone.

Abstract: The present invention relates to a triblock copolymer, that is multipurpose yet has sufficient properties particularly for medical applications, and is useful as a material having excellent flexibility and water absorbability, as well as to a method for producing the same, and a biocompatible material. The copolymer of the present invention is composed of segments A1 and A2 each composed of a polymer having a depsipeptide unit, such as a segment selected from a homopolymer of depsipeptide or a copolymer of lactide and depsipeptide, and segment B composed of polyalkylene glycol, such as PEG, and is a A1-B-A2 triblock copolymer having a number average molecular weight of 8000 to 500000. The biocompatible material of the present invention contains the triblock copolymer as a main component, and may be used as a tissue anti-adhesion barrier.

Abstract: This invention relates to stents coated with hydrophilic polymers containing S-nitrosothiols, which are able to provide local delivery of both nitric oxide and S-nitrosothiols by diffusion. This device is intended for coronary angioplasty applications with the purpose of inhibiting acute and chronic restenosis and refers to processes of stent coating with hydrophilic polymers containing incorporated S-nitrosothiols. This invention refers to an intracoronary implant device used in medical procedures, and introduces new S nitrosothiol-eluting stents coated with hydrophilic polymer multilayers. The hydrophilic polymers used for coating are polyvinyl alcohol, polyvinylpirrolidone and polyvinyl alcohol/polyvinylpirrolidone, polyvinyl alcohol/polyethylene glycol, polyvinylpirrolidone/polyethylene glycol and polyvinyl alcohol/polyvinylpirrolidone/polyethylene glycol blends.

Abstract: Thermogelling polymers are described containing poly (n-isopropyl acrylamide). Solutions of this polymer, copolymers or mixtures of the polymer with a second polymer such as poly(ethylene glycol), poly (vinyl pyrrolidone) or poly(vinyl alcohol) are liquids at room temperature and solids at body temperature. Thus, also provided are methods of implanting a hydrogel into a mammal by injecting the solution as a liquid at a temperature below body temperature into a selected site in the mammal at a temperature below body temperature, which then undergoes thermal phase transition to form a solid hydrogel in situ in the body as the implant warms to body temperature. Methods for using these thermal gelling materials in various applications including nucleus pulposus replacement/augmentation, wound care, disk replacement, cartilage replacement, joint replacement, surgical barriers, gastrointestinal devices, cosmetic and reconstructive surgery, and breast enlargement are also provided.

Abstract: Provided herein is a copolymer that includes a soft block (A) and a hard block (B) comprising a tyrosine di-peptide. The copolymer can be any of AB, ABA or BAB type block copolymers. The soft block can include a PEA polymer. A coating formed of the copolymer may also include a bioactive agent. The implantable device can be implanted in a patient to treat, prevent, or ameliorate a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, and/or tumor obstruction.

Abstract: Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.

Abstract: The present invention provides a bone in-growth surface for implants which has a structure for delivering therapeutic agents to surrounding bone and tissue. The bone in-growth surface may comprise scaffolding and a controlled-permeability layer which contains the therapeutic agents in a variety of reservoirs. The porosity of the scaffolding may be controllable from zero porosity to essentially a fully porous material.

Abstract: The present invention relates to a method for the treatment of skeletal dysplasia by administering to a patient a composition comprising a therapeutically effective amount of at least one C-type natriuretic peptide (CNP).

Abstract: A re-rollable membrane for wrapping around and protecting a cylindrical tissue having an injury site. The membrane includes a sheet of a porous matrix formed of cross-linked biopolymeric fibers. In one implementation, the sheet can be spirally rolled so that at least one portion overlaps another portion of the sheet and, upon absorption of a fluid, the overlapping portions adhere to each other closely so as to exclude penetration of cells. In another implementation, the sheet can be helically rolled to form a helix having a pitch of 2 mm to 40 mm and an inner diameter of 1 mm to 50 mm. Also disclosed are methods for making and using such re-rollable membranes.

Abstract: Methods, systems, and uses of bucky paper are provided in the present invention. These embodiments include covering medical implants with single or multiple layers of bucky paper, treating bucky paper with various therapeutics to be released through the bucky paper to a target site, shaping bucky paper into non-conventional configurations for improved therapeutic deliver, and using bucky paper alone or in conjunction with other materials to treat a target site.

Abstract: The present invention relates in one aspect to the use of a matrix gel comprising chondrocytes or progenitor cells thereof in a density below that of natural cartilage as a cartilage repair implant wherein said cells exhibit increases production of extracellular matrix material.

Abstract: The present invention provides a method for forming on a medical device, preferably an ophthalmic lens, more preferably a contact lens, a diffusion-controllable coating capable of controlling the out-diffusion or release of guest materials from the medical device. The method of the invention comprises: (1) applying one layer of clay and optionally one or more layers of polyionic materials onto the medical device; or (2) applying alternatively a layer of a first polyionic material and a layer of a second polyionic material having charges opposite of the charges of the first polyionic material onto the medical device and releasing the coated medical device into a releasing medium having a composition capable of imparting a desired permeability to the diffusion-controllable coating on the medical device.

Abstract: An article comprising two chemically grafted polymer layers comprising a hydrogel layer and an end-functionalized polyurethane layer. The invention also includes methods of making and using the article.

Abstract: Biocompatible amino acid anhydride polymers for use in tissue engineering, and methods for their preparation and use.

Abstract: An improved drug delivery composition and method of use is disclosed. The composition comprises one or more biodegradable block copolymer drug carriers; and a reconstitution enhancing and enabling agent comprising polyethylene glycol (PEG), a PEG derivative or a mixture of PEG and a PEG derivative. The composition can be administered as is or after being be dissolved or rapidly reconstituted in an aqueous vehicle to afford a homogeneous solution or uniform colloidal systems.

Abstract: The present invention generally encompasses a medical article, such as a medical device or coating comprising an agent or combination of agents, wherein the agent is distributed throughout a polymeric matrix. The polymeric matrix comprises an agent and a poly(ester amide) having a design that was preselected to provide a predetermined release rate of the combination of agents from the medical article.

Abstract: Methods, systems, and uses of bucky paper are provided in the present invention. These embodiments include covering medical implants with single or multiple layers of bucky paper, treating bucky paper with various therapeutics to be released through the bucky paper to a target site, shaping bucky paper into non-conventional configurations for improved therapeutic deliver, and using bucky paper alone or in conjunction with other materials to treat a target site.

Abstract: ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; have a long life span; are of human origin; have good in vivo device viability; deliver efficacious quantity of growth factor; trigger no or low level host immune reaction, and are non-tumorigenic.

Abstract: The present invention provides insertable medical devices having elastic surfaces associated with bioactive agent-containing microparticulates and a coating material. Upon expansion of the elastic surfaces the microparticulates can be released to a subject.

Abstract: A pharmaceutical composition containing a water-soluble fraction of Graptopetalum and its use in treating a liver disease or condition, such as inflammation, steatosis, and fibrosis.

Abstract: A polymer coating for medical devices based on a polyolefin derivative. A variety of polymers are described to make coatings for medical devices, particularly, for drug delivery stents. The polymers include homo-, co-, and terpolymers having at least one olefin-derived unit and at least one unit derived from vinyl alcohol, allyl alcohol and derivatives thereof.

Abstract: The invention provides a nutritional supplement system and program for patients undergoing or who have undergone a surgical or other invasive or stressful procedure, or who have suffered an injury. This nutritional supplement for the peri-operative period is designed to prevent deficiencies of nutrients needed for optimal health and healing during this period or for general application and to enable the person receiving the nutritional supplementation to achieve maximum healing and rapid recovery from a procedure or injury.

Abstract: Embodiments of the present invention are directed to three-dimensional porous structures for modulating intraocular pressure. The structures can include a mixture of copolymers, for example, collagen and glycosaminoglycan.

Abstract: The present invention provides compositions and methods for modulating smooth muscle cells. The present invention also provides methods of identifying small molecule candidate therapeutic agents for modulating smooth muscle.

Abstract: A medical article comprising: (a) a therapeutic agent; and (b) a release region comprising (i) a polymer and (ii) a filler comprising inorganic platelet particles. Upon placement of such a medical article at a position on or within a patient, the release region regulates the rate of release of the therapeutic agent from the medical article to the patient. An example of a filler is one comprising inorganic platelet particles. Examples of medical articles include, for instance, drug delivery patches, and implantable or insertable medical devices. Also described are methods of releasing a therapeutic agent to a patient using such medical articles, and methods of making such medical articles.

Abstract: Therapeutic compositions, devices and protocols for the treatment of keloids and other abnormal scars with improved appearance and a much lower recurrence rate. A therapeutic drug delivery device comprises an injectable mixture of a fibroblast inhibitor such as corticosteroid and a slow release carrier such as milled gel sponge dispersed in a fluid medium such as biological saline. The composition can be injected perilesionally in the dermis following excision of the keolid or other scar tissue, to circumscribe the wound. The infiltration of the mixture around the wound can provide a slow release of the fibroblast inhibitor for an extended period of time until normal wound closure can dominate and keloid or abnormal scar recurrence is inhibited.

Abstract: A composition is provided that allows for treatment of cancer, prophylactic treatment, and treatment of infection in the urinary tract. The composition comprises a nitric oxide (NO) eluting polymer that elutes nitric oxide (NO) in a therapeutic dose. The nitric oxide (NO) eluting polymer may be integrated with a carrier material, such that said carrier material, in use, regulates and controls the elution of said therapeutic dosage of nitric oxide (NO). The nitric oxide (NO) eluting polymer may be provided as a Solution or Suspension. Furthermore, a manufacturing method for said composition is disclosed, as well as uses of said composition in the urinary tract.

Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on secreted therapeutic proteins, NsG29 and NsG31. NsG29 and Ns31 are members of a newly identified family of growth factors with a specific cystein pattern and characterised by expression in the nervous system. The secreted growth factors have potential for the treatment of disorders of the nervous system. The invention also relates to bioactive NsG29 and NsG31 polypeptide fragments and the corresponding encoding DNA sequences.

Abstract: A luminal stent, implanted and implanted and left in the blood vessel, is disclosed. By permitting a stent (1), formed of a biodegradable polymer material (2), to be swollen, and by impregnating the swollen stent (1) with a drug, a sufficient quantity of the drug is impregnated in the stent. This drug is continuously released into the blood vessel over a prolonged time. A biodegradable polymer layer is formed on the surface of the stent (1) impregnated with the drug, and the release rate of the drug impregnated in the stent is controlled.

Abstract: The present invention generally relates to a method of using a matrix as a barrier for unwanted cell attachment and bone formation in unwanted areas of the human body during implant procedures. More specifically, a growth-inhibiting matrix may be used to prevent migration of osteo-inductive agents or bone tissue from an intervertebral disc space through the outer bands of annulus fibrosis that abuts the spinal tissue, canal, and other surrounding areas.

Abstract: The invention relates to the use of one or more growth factors in a drug delivery system, optionally with an external mesh housing, to recruit and optionally harvest progenitor cells. These cells include those that normally reside in the bone marrow.

Abstract: The present invention provides a method for mineralizing commercially available guided bone regeneration membranes. The method comprises the steps of (a) providing a commercially available guided bone regeneration membrane, (b) applying a mineralizing solution, and (c) microwaving the membrane. The method may further comprise (d) rinsing the membrane in a solution such as distilled water and (e) drying the membrane. The mineralizing solution may be a solution capable of supplying or delivering a mineral such as calcium or zinc. The invention further provides guided bone regeneration membranes made by the methods described. The guided bone regeneration membrane comprises a mineral, such as, for instance calcium or zinc at a weight percent of at least 5%, at least 10%, at least 12%, at least 15%, at least 18%, at least 20% or at least 25% (weight percent) of the membrane. Further, the invention provides methods for enhancing bone regeneration and methods for inhibiting bacterial infection and inflammation.

Abstract: An injectable slow-release methadone, partial opioid agonist or opioid antagonist formulation is provided comprising methadone, a partial opioid agonist or opioid antagonist in a poly(D,L-lactide) excipient with a small amount of residual ethyl acetate. Upon intramuscular or subcutaneous injection of the composition, methadone, a partial opioid agonist or opioid antagonist is released in a controlled manner over an extended period of time. The composition finds use in the treatment of heroin addicts and alcoholics to reduce consumption of the abused substances. Of particular interest are the drugs buprenorphine, methadone and naltrexone.

Abstract: This invention relates to graft copolymer delivery vehicles comprising a polyethyleneglycol-poly(ortho ester), and to controlled release pharmaceutical compositions comprising the delivery vehicle and an active agent. The graft copolymer delivery vehicles may be thermogels graft copolymers. The pharmaceutical compositions may be in the form of a topical, syringable, or injectable formulation for local controlled delivery of the active agent.

Abstract: According to an aspect of the present invention, a medical device is provided which comprises a metallic substrate and polymeric region disposed over and in contact with the metallic substrate. The polymeric region comprises (a) a block copolymer that comprises (i) a hard polymer block that comprises a high Tg monomer and (ii) a soft polymer block that comprises a low Tg monomer, (b) an adhesion promoting copolymer that comprises (i) a first monomer that covalently or non-covalently bonds with the metallic substrate and (ii) a second monomer that is compatible with the low Tg monomer and/or the high Tg monomer and (c) a therapeutic agent. The polymeric region may further comprise an optional polymer that is used to tailor the release rate of the therapeutic agent.

Abstract: The invention provides fabricated hydrogels, hydrogel particles, hydrogel containing compositions, and methods of making the same. The invention also provides methods of implanting, injecting, or administering the hydrogels, hydrogel particles, or the hydrogel containing compositions to treat a subject in need. Methods of crosslinking pre-solidified or pre-gelled hydrogel particles and making crosslinked hydrogels, crosslinked hydrogel particles, and crosslinked hydrogel containing compositions also are disclosed herein.

Abstract: Methods and devices transmit micromechanical forces locally on the millimeter to micron scale for promoting wound healing. Micromechanical forces can selectively be applied directly to tissue, in some embodiments, by using microchambers fluidically connected to microchannels. Each chamber, or in some cases, group of chambers, may be associated with a valve to control vacuum pressure, positive pressure, liquid delivery, and/or liquid removal from each chamber or group of chambers. Application of embodiments of the invention may shorten wound-healing time, reduce costs of therapy, enable restoration of functional tissue, and reduce the need for more invasive therapies, including surgery.

Abstract: Compositions suitable for use as adjuvants in the preparation of vaccines, particularly those vaccines useful in the treatment of cancer, are provided. Methods for inhibiting tumor growth in an animal are also disclosed. Methods for immunizing an animal against cancer, such as prostate cancer, are also described. The adjuvants described are comprised of an extracellular matrix material, such as small intestinal submucosal (SIS) tissue. The preparations may take the form of sheets, gels, liquids (injectable), trocar, or other solid or semi-solid preparation. The invention provides for enhanced tumor inhibition of 2-fold or greater, compared to vaccine preparations without the extracellular matrix material, or from 4- to 5-fold, compared to preparations without the adjuvant promoting extracellular materials.

Abstract: Carotenoids are extracted and/or enriched from a mixture containing such compounds. The extraction/enrichment process involves the use of liquefied or supercritical solvents to extract lipids and carotenoids from carotenoid-containing substrates. The extraction process can also be performed in two steps in which lipids and carotenoids are first removed from a carotenoid-containing substrate with a liquefied or supercritical solvent, and subsequently a liquefied or supercritical gas is used to separate the lipids from the carotenoids. The two step process can be reversed to first extract lipids with the liquefied or supercritical gas, and subsequently use the solvent to extract the carotenoids. The process is also applicable to yield an organic solvent-free product from a carotenoid-containing source that was first extracted using an organic solvent.

Abstract: The present invention provides an implant for positioning within a particularly dimensioned body cavity. The implant is reversibly deformable between an expanded state and a compressed state. The implant is constructed and arranged for insertion within the body cavity when in its compressed state, and pressurelessly conforms to the cavity dimensions in its expanded state. Particularly, the implant is characterized by spontaneous deformation to the expanded state in situ within the body cavity while retaining and/or absorbing at least one flowable constituent as a function of its degree of deformation.

Abstract: A method for producing a non-chemically crosslinked hyaluronan is provided which involves contacting a sample of hyaluronan with an acidic solvent/water mixture for a period of time and at a temperature sufficient to effect crosslinking, wherein the acidic solvent/water mixture has a content of a solvent sufficient to prevent dissolution of said hyaluronan and wherein the solvent is miscible with water, and an amount of an acid sufficient to effect crosslinking of the hyaluronan, and the crosslinked, water resistant non-woven hyaluronan resulting therefrom.

Abstract: A polymer coating for medical devices based on a derivatized poly(ethylene-co-vinyl alcohol) is disclosed. A variety of polymers are described to make coatings for medical devices, particularly, for drug delivery stents. The polymers include poly(ethylene-co-vinyl alcohol) modified by alkylation, esterification, and introduction of fluorinated alkyl fragments, polysiloxane fragments and poly(ethylene glycol) fragments into the macromolecular chains of poly(ethylene-co-vinyl alcohol).

Abstract: A method for coating a medical device with a drug is provided. Energy, preferably thermal energy, is applied to a crystalline deposit of a drug on the surface of a medical device to increase the molecular mobility and form a conformable drug coating with a low density of micro-cracks and other mechanical defects that can degrade the coating toughness and effective adhesion to the device surface. In a preferred embodiment, solution evaporation methods are used to deposit a crystalline coating of an anti-inflammatory steroid on a medical electrode. Heat applied at a controlled temperature, for a predetermined amount of time, induces a solid-state phase change of the drug coating providing a smooth, uniform, well-attached, conformable coating to form a layer that will elute from the electrode over time when implanted in a patient's body.

Abstract: The invention provides compositions comprising an RAR antagonist for promoting chondrogenesis and methods employing such compositions for treating cartilage and associated bone abnormalities resulting from injury or disease and for ex vivo tissue engineering.

Abstract: Biodegradable and/or bioabsorable fibrous articles and methods for using the articles in medical applications are disclosed. The biodegradable and/or bioabsorable fibrous articles, which are formed by elctrospinning fibers of biodegradable and/or bioabsorbable fiberizable material, comprise a composite (or asymmetric composite) of different biodegradable and/or bioabsorbable fibers. Articles having specific medical uses include an adhesion-reducing barrier and a controlled delivery system. The methods include methods for reducing surgical adhesions, controlled delivery of a medicinal agent and providing controlled tissue healing.

Abstract: An osmotic delivery system for controlled delivery of a beneficial agent includes an implantable capsule containing a beneficial agent and an osmotic engine that swells on contact with water, thereby causing the release of the beneficial agent over time. The osmotic delivery system has a membrane material that allows a controlled amount of fluid to enter from an exterior of the capsule, while preventing the compositions within the capsule from passing out of the capsule. The osmotic delivery system is designed to meet at least the operating pressures of 1000 psi. The membrane material is cast, calendered or extruded followed by machining (i.e., die-cutting, stamping or otherwise cutting to shape) to provide a uniform nonribbed membrane material. The capsule also includes a membrane material-retaining means that is positioned at a fluid uptake end to retain the membrane material within the capsule, even under periods of high pressure.

Abstract: An injectable composition for delivery of a bioactive agent contains a biocompatible solvent, a hydrophobic polymer, and an amphiphilic block copolymer. The hydrophobic polymer may be a biodegradable polymer, and the block copolymer may contain a segment of poly(ethylene oxide).

Abstract: The present invention provides a system for treating a vascular condition, including a catheter, a stent coupled to the catheter, a drug-polymer coating on the stent including a polymeric blend of a phenoxy polymer and a styrenic block copolymer, and a bioactive drug dispersed within the drug-polymer coating.

Abstract: The present patent describes a biocompatible composite made of a first fibrous layer attached to a three-dimensional inter-connected open cell porous foams that have a gradient in composition and/or microstructure through one or more directions. These composites can be made from blends of absorbable and biocompatible polymers. These biocompatible composites are particularly well suited to tissue engineering applications and can be designed to mimic tissue transition or interface zones.

Abstract: The present invention provides an improved technique for spinal fusion involving the administration of an HMG-CoA reductase inhibitor to a fusion. The HMG-CoA reductase inhibitor is preferably delivered to the site by a carrier. More preferably, the HMG-CoA reductase inhibitor is delivered to the site by a non-compressible delivery vehicle. The invention is suitable for promoting non-anatomic or heterotopic bone growth between any bony surfaces where bone growth is desired but does not naturally occur.